In 540 patients with unresectable stage III or stage IV melanoma who had not responded to ipilimumab plus BRAF/MEK inhibitor therapy (if BRAF V600 mutant), two doses of pembrolizumab (2 mg/kg and 10 mg/kg) were compared with investigator-choice chemotherapy in the randomised phase 2 KEYNOTE-002 study [48]. Here, MAP2K7 is linked to melanoma.